



AIN GROUP

FY4/24 1Q Supplementary Materials

AIN HOLDINGS INC.

September 1, 2023

1. Consolidated Results

■ Year-on-Year

(¥ million)	FY4/23 1Q results	FY4/24 1Q results	YoY change	YoY change(%)
Net sales	81,470	94,654	+13,184	+16.2
Gross profit % of net sales	11,643 14.3	13,199 13.9	+1,556	+13.4
SG&A expenses % of net sales	8,889 10.9	9,588 10.1	+699	+7.9
Operating profit % of net sales	2,753 3.4	3,610 3.8	+857	+31.1
Ordinary profit % of net sales	3,090 3.8	3,881 4.1	+791	+25.6
Profit attributable to owners of parent % of net sales	1,704 2.1	2,140 2.3	+436	+25.6
Earnings per share(¥)	48.54	60.93	+12.39	+25.5

► Figures in the table are rounded down

► FY4/23 1Q: Reflect finalized figures of provisional accounting treatment related to business combination

■ Vs Plan

(¥ million)	FY4/24 1Q plan	FY4/24 1Q results	Vs plan change	Vs plan change(%)
Net sales	90,055	94,654	+4,599	+5.1
Gross profit % of net sales	11,942 13.3	13,199 13.9	+1,257	+10.5
SG&A expenses % of net sales	9,683 10.8	9,588 10.1	(95)	(1.0)
Operating profit % of net sales	2,259 2.5	3,610 3.8	+1,351	+59.8
Ordinary profit % of net sales	2,425 2.7	3,881 4.1	+1,456	+60.0
Profit attributable to owners of parent % of net sales	1,000 1.1	2,140 2.3	+1,140	+114.0
Earnings per share(¥)	28.49	60.93	+32.44	+113.9

► Figures in the table are rounded down

2. Segment Information (Dispensing Pharmacy Business)

■ Year-on-Year

(¥ million)	FY4/23 1Q results	FY4/24 1Q results	YoY change	YoY change(%)
Net sales	72,482	84,405	+11,923	+16.4
Gross profit % of net sales	8,328 11.5	9,349 11.1	+1,021	+12.3
SG&A expenses % of net sales	3,840 5.3	4,150 4.9	+310	+8.1
Operating profit % of net sales	4,487 6.2	5,198 6.2	+711	+15.8
Segment profit % of net sales	4,732 6.5	5,429 6.4	+697	+14.7

▶ Figures in the table are rounded down

▶ Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

▶ FY4/23 1Q: Reflect finalized figures of provisional accounting treatment related to business combination

■ Vs Plan

(¥ million)	FY4/24 1Q plan	FY4/24 1Q results	Vs plan change	Vs plan change(%)
Net sales	80,440	84,405	+3,965	+4.9
Gross profit % of net sales	8,362 10.4	9,349 11.1	+987	+11.8
SG&A expenses % of net sales	4,160 5.2	4,150 4.9	(10)	(0.2)
Operating profit % of net sales	4,202 5.2	5,198 6.2	+996	23.7
Segment profit % of net sales	4,355 5.4	5,429 6.4	+1,074	24.7

▶ Figures in the table are rounded down

▶ Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

3. Segment Information (Cosmetic and Drug Store Business)

■ Year-on-Year

(¥ million)	FY4/23 1Q results	FY4/24 1Q results	YoY change	YoY change(%)
Net sales	6,086	7,412	+1,326	+21.8
Gross profit % of net sales	2,245 36.9	2,855 38.5	+610	+27.2
SG&A expenses % of net sales	2,098 34.5	2,149 29.0	+51	+2.4
Operating profit % of net sales	146 2.4	706 9.5	+560	+383.6
Segment profit % of net sales	164 2.7	710 9.6	+546	+332.9

► Figures in the table are rounded down

► Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

■ Vs Plan

(¥ million)	FY4/24 1Q plan	FY4/24 1Q results	Vs plan change	Vs plan change(%)
Net sales	6,830	7,412	+582	+8.5
Gross profit % of net sales	2,571 37.6	2,855 38.5	+284	+11.1
SG&A expenses % of net sales	2,261 33.1	2,149 29.0	(112)	(5.0)
Operating profit % of net sales	310 4.5	706 9.5	+396	+127.7
Segment profit % of net sales	310 4.5	710 9.6	+400	+129.0

► Figures in the table are rounded down

► Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

4. Sales Verification

■ Dispensing Pharmacy Business (YoY)

(%)	Net sales	Prescription volume	Average prescription price
Same store (1,071)	+8.1	+6.7	+1.3
Store openings in the previous year (134)	+268.7	+246.3	+7.2
Total (1,215)	+16.9	+14.9	+1.7

■ Dispensing Pharmacy Business (Vs Plan)

(%)	Net sales	Prescription volume	Average prescription price
Same store (1,071)	+5.1	+3.9	+1.2
Store openings in the previous year (134)	+6.1	+4.5	+1.6
Total (1,215)	+5.0	+4.0	+1.0

▶ YoY: Reflect finalized figures of provisional accounting treatment related to business combination

■ Cosmetic and Drug Store Business (YoY)

(%)	Net sales	Number of customers	Average spending per customer
Same store (69)	+24.9	+13.1	+10.4
Store openings in the previous year (8)	+453.0	+422.4	+5.9
Total (78)	+21.8	+11.4	+9.3

■ Cosmetic and Drug Store Business (Vs Plan)

(%)	Net sales	Number of customers	Average spending per customer
Same store (69)	+9.0	(2.6)	+11.9
Store openings in the previous year (8)	+10.2	+8.0	+2.0
Total (78)	+8.5	(2.2)	+11.0

5. Consolidated Balance Sheet

■ Assets

(¥ million)	End-FY4/23 1Q	End-FY4/23	End-FY4/24 1Q	Change
Cash on hand and in banks	46,863	46,796	47,373	+577
Accounts receivable	12,697	13,249	12,719	(530)
Inventories	19,504	21,586	24,340	+2,754
Total current assets	96,163	98,305	101,400	+3,095
Buildings and structures, net	19,505	21,407	23,336	+1,929
Land	10,637	10,602	10,481	(121)
Total property, plant and equipment	35,755	39,459	40,113	+654
Goodwill	49,449	46,443	45,611	(832)
Total intangible fixed assets	54,584	52,343	51,613	(730)
Investments in securities	2,649	2,720	2,791	+71
Deferred tax assets	6,012	5,990	5,974	(16)
Deposits and guarantees	23,234	24,507	24,950	+443
Total investments and other assets	42,050	41,641	42,520	+879
Total fixed assets	132,390	133,444	134,246	+802
Total assets	228,553	231,750	235,647	+3,897

- ▶ Figures in the table are rounded down
- ▶ Change: End-FY4/24 1Q compared with end-FY4/23
- ▶ Capital expenditures (Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥2,953million
- ▶ End-FY4/23 1Q: Reflect finalized figures of provisional accounting treatment related to business combination

■ Liabilities and Net Assets

(¥ million)	End-FY4/23 1Q	End-FY4/23	End-FY4/24 1Q	Change
Accounts payable	59,462	58,698	64,859	+6,161
Short-term debt	4,167	3,670	3,648	(22)
Total current liabilities	91,402	92,986	97,840	+4,854
Long-term debt	11,218	5,021	3,848	(1,173)
Total long-term liabilities	18,376	12,218	11,189	(1,029)
Total liabilities	109,779	105,204	109,029	+3,825
Common stock	21,894	21,894	21,894	-
Capital surplus	20,500	20,504	20,504	-
Retained earnings	78,434	85,963	85,996	+33
Total shareholders' equity	118,811	126,362	126,394	+32
Total net assets	118,774	126,546	126,617	+71
Total liabilities and net assets	228,553	231,750	235,647	+3,897

- ▶ Figures in the table are rounded down
- ▶ Change: End-FY4/24 1Q compared with end-FY4/23
- ▶ End-FY4/23 1Q: Reflect finalized figures of provisional accounting treatment related to business combination

6. FY4/24 Plan (Consolidated)

(¥ million)	FY4/22 results	FY4/23 results	FY4/24 plan	YoY change	YoY change (%)
Net sales	316,247	358,742	375,000	+16,258	+4.5
Gross profit % of net sales	49,971 15.8	53,698 15.0	55,413 14.8	+1,715	+3.2
SG&A expenses % of net sales	34,832 11.0	37,694 10.5	39,750 10.6	+2,056	+5.5
Operating profit % of net sales	15,139 4.8	16,004 4.5	15,663 4.2	(341)	(2.1)
Ordinary profit % of net sales	16,041 5.1	17,064 4.8	16,302 4.3	(762)	(4.5)
Profit attributable to owners of parent % of net sales	7,092 2.2	9,234 2.6	8,250 2.2	(984)	(10.7)
Earnings per share(¥)	201.47	262.87	234.84	(28.03)	(10.7)
Annual dividend (¥)	55.00	60.00	60.00	-	-

► Figures in the table are rounded down

► Change: FY4/24 plan compared with FY4/23 results

7. Transition of Store Openings

■ Number of Store Openings in Dispensing Pharmacy Business

	FY4/16	FY4/17	FY4/18	FY4/19	FY4/20	FY4/21	FY4/22	FY4/23	FY4/24 1Q
Organic	32	27	25	23	14	15	25	27	5
M&A	110	182	11	134	6	14	24	114	5
Total	881	1,066	1,029	1,132	1,088	1,065	1,099	1,209	1,215

■ Number of Store Openings in Cosmetic and Drug Store Business

	FY4/16	FY4/17	FY4/18	FY4/19	FY4/20	FY4/21	FY4/22	FY4/23	FY4/24 1Q
Organic	5	9	4	7	15	11	12	8	1
Total	52	52	48	54	63	69	78	78	78

Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
<https://www.ainj.co.jp/corporate/>

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.



AIN GROUP